Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Edward Morrow Atkinson III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently sold a significant portion of his holdings in the ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

(Reuters) - Vertex Pharmaceuticals forecast annual revenue largely ... which treats a rare blood disorder requiring regular blood transfusions. The Boston, Massachusetts-based drugmaker developed ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...

Lattice Semiconductor Corporation , the low power programmable leader, today announced multiple new executive leadership team members. Lorenzo Flores joined the company as Chief Financial Officer, ...